Samuraciclib is under clinical development by Carrick Therapeutics and currently in Phase II for Ovarian Cancer. According to GlobalData, Phase II drugs for Ovarian Cancer have a 26% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Samuraciclib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Samuraciclib overview
Samuraciclib (CT-7001) is under development for the treatment of triple negative breast cancer, metastatic or locally advanced HR+ and HER2- breast cancer, colorectal cancer, ovarian cancer, prostate cancer, and small-cell lung cancer. It is administered through the oral route. The drug candidate acts by targeting cyclin-dependent kinase 7 (CDK7).
It was also under development for acute myeloid leukemia.
Carrick Therapeutics overview
Carrick Therapeutics is a biopharmaceutical company that focuses on the research and development of cancer therapies. The company develops drugs that target the molecular pathways of the most aggressive and resistant forms of cancer. In addition, the company strives to advance its programs by comprehending the cancer-causing mechanisms and combining them with the latest technologies to identify treatments. It works in collaboration with a cancer research charity, Cancer Research UK and academic institutions such as Cambridge University, Oxford University, and Imperial College, to discover and develop cancer medicines. The company has a presence in Ireland and the UK. Carrick Therapeutics is headquartered in Dublin, Ireland.
For a complete picture of Samuraciclib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
